Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111247 | 1.00 | PRKCZ (0.46) | PRKCZADRA2AADRA2BADRA2CADRA1A | |
| Iodide SCHEMBL27879062 | 0.98 | PRKCZ (0.44) | PRKCZADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL27680594 | 0.90 | PRKCZ (0.40) | PRKCZADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL9871846 | 0.82 | CYP3A4 (0.46) | PRKCZADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL4068814 | 0.80 | HASPIN (0.39) | PRKCZADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL12441263 | 0.76 | IMPDH2 (0.48) | ADRA2AADRA2BADRA2CADRA1AKDM4E | |
| SCHEMBL20873066 | 0.75 | PRKCZ (0.64) | PRKCZADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL19656321 | 0.74 | IMPDH2 (0.47) | PRKCZADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL29862478 | 0.74 | IMPDH2 (0.47) | PRKCZADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL6993140 | 0.74 | CYP11B1 (0.44) | PRKCZKDM4ECYP11B2CYP11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202816-B2 | Compounds as NADPH oxidase inhibitors | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2025-01-21 | — | — | US | disclosed |
| EP-4081299-B1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2024-09-25 | — | — | EP | disclosed |
| EP-4333819-A1 | TREATMENT OF PHARMACORESISTANT EPILEPSY | Katholieke Universiteit Leuven (BE) | 2024-03-13 | — | — | EP | disclosed |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2023-06-22 | — | — | US | disclosed |
| WO-2023081452-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022233877-A1 | TREATMENT OF PHARMACORESISTANT EPILEPSY | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-11-10 | — | — | WO | disclosed |
| EP-4081299-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2022-11-02 | — | — | EP | disclosed |
| US-11479546-B2 | Antimalarial hexahydropyrimidine analogues | UCB Biopharma SRL | 2022-10-25 | — | — | US | disclosed |
| US-20220033379-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479546-B2 | Antimalarial hexahydropyrimidine analogues | G6PD, DPYD, DHODH | PRKCZ 4030/4885ADRA2A 2928/4885ADRA2B 2728/4885 |
| US-12202816-B2 | Compounds as NADPH oxidase inhibitors | CYBB, NOX1, NOX4 | PRKCZ 1087/4885ADRA2A 2520/4885ADRA2B 1773/4885 |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | FCER2, FCGR2A, FCGR1A | PRKCZ 539/4885ADRA2A 302/4885ADRA2B 343/4885 |
| US-20220033379-A1 | NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS | CYBB, NOX1, NOX4 | PRKCZ 935/4885ADRA2A 2422/4885ADRA2B 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.